Hanmi Pharmaceutical Co. Ltd

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Manufacturing

GEA secures first-of-a-kind pharma order from Hanmi Pharmaceutical

Hanmi chose GEA as key vendor for a new plant under construction in South Korea
Research & Development

Janssen and Hanmi agree to develop a novel clinical-stage biologic to treat diabetes and obesity

Commercialisation of oxyntomodulin-based therapy will bolster Janssen's metabolism portfolio
Regulatory

AZ enters agreement with Hanmi and Amneal in US Nexium patent litigation

AZ says this removes need for a trial and avoids ‘considerable’ costs
Subscribe now